Lactobacillus casei LC89 exerts antidiabetic effects through regulating hepatic glucagon response and gut microbiota in type 2 diabetic mice

Food Funct. 2021 Sep 20;12(18):8288-8299. doi: 10.1039/d1fo00882j.

Abstract

Previous study suggests that Lactobacillus casei exhibits antihyperglycemic activity, however, the molecular mechanism of this has yet to be elucidated. Here, the anti-diabetic effects and underlying mechanisms of Lactobacillus casei LC89 are investigated in type 2 diabetes mellitus (T2DM) mice, which was induced by a high-fat diet (HFD) with streptozotocin (100 mg per kg BW). The results show that LC89 at a dose of 109 CFU day-1 decreases fasting blood glucose (FBG) and insulin levels by 35.12% and 28.37%, respectively, compared to the diabetes control (DC) group. Moreover, LC89 treatment improved the insulin resistance index (HOMA-IR), serum lipid profiles and inflammation cytokines. The real-time polymerase chain reaction indicated that LC89 markedly downregulates the mRNA expression of hepatic glucagon (GCG), glucagon receptor (GCGR), phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase). Meanwhile, LC89 significantly decreases the abundance of Odoribacter, but increases the Alloprevotella, Bacteroides, Parabacteroides and Ruminococcus content. Therefore, LC89 plays a positive role in alleviating T2DM by regulating gut microbiota and glucagon signal pathway-related genes, and it may be a beneficial dietary supplement to regulate glucose metabolism in T2DM.

MeSH terms

  • Animals
  • Blood Glucose
  • DNA, Bacterial / genetics
  • Diabetes Mellitus, Type 2 / chemically induced
  • Diabetes Mellitus, Type 2 / therapy*
  • Diet, High-Fat
  • Dietary Fats / administration & dosage
  • Dietary Fats / adverse effects
  • Gastrointestinal Microbiome*
  • Glucagon / metabolism*
  • Glycogen / genetics
  • Glycogen / metabolism
  • Hypoglycemic Agents
  • Insulin / blood
  • Lacticaseibacillus casei*
  • Liver / drug effects*
  • Liver / metabolism
  • Male
  • Metformin / therapeutic use
  • Mice
  • Probiotics / therapeutic use
  • RNA, Bacterial / genetics
  • RNA, Ribosomal, 16S / genetics
  • Random Allocation

Substances

  • Blood Glucose
  • DNA, Bacterial
  • Dietary Fats
  • Hypoglycemic Agents
  • Insulin
  • RNA, Bacterial
  • RNA, Ribosomal, 16S
  • Glycogen
  • Glucagon
  • Metformin